Medication comparison
Semaglutide vs Tirzepatide
Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors. Both have specific FDA-approved products and indications, and the appropriate option depends on diagnosis, eligibility, risks, access, and clinician guidance.
This page does not recommend one medication over another.
Quick comparison
Semaglutide and tirzepatide differ by mechanism, products, and indications
The comparison below is educational. Clinicians should explain which FDA-approved product, if any, fits the patient's diagnosis, risks, access, and goals.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class or mechanism | Semaglutide A GLP-1 receptor agonist. | Tirzepatide A dual GIP and GLP-1 receptor agonist. |
| Approved product examples | Semaglutide Wegovy, Ozempic, and Rybelsus have different labels and uses. | Tirzepatide Zepbound and Mounjaro have different labels and uses. |
| Approved uses | Semaglutide Certain products are approved for chronic weight management; others are approved for type 2 diabetes-related indications. | Tirzepatide Zepbound is approved for chronic weight management and other labeled uses; Mounjaro is approved for type 2 diabetes-related use. |
| Common dosing format | Semaglutide Product forms vary by label and include injectable and oral products depending on brand. | Tirzepatide FDA-approved products are injectable. |
| Common side effects | Semaglutide Gastrointestinal side effects are common and product labels list additional warnings. | Tirzepatide Gastrointestinal side effects are common and product labels list additional warnings. |
| Major warnings | Semaglutide Labels include thyroid C-cell tumor warning and other product-specific warnings. | Tirzepatide Labels include thyroid C-cell tumor warning and other product-specific warnings. |
| Access and cost | Semaglutide Coverage depends on product, indication, insurance, supply, and prior authorization rules. | Tirzepatide Coverage depends on product, indication, insurance, supply, and prior authorization rules. |
How semaglutide works
Semaglutide acts on the GLP-1 receptor
Semaglutide is the active ingredient in products with different approved uses. Wegovy is used for chronic weight-management indications, while Ozempic and Rybelsus are used for type 2 diabetes-related indications.
How tirzepatide works
Tirzepatide acts on both GIP and GLP-1 receptors
Tirzepatide is the active ingredient in Zepbound and Mounjaro. Zepbound and Mounjaro are not interchangeable labels; clinicians should explain which product fits the diagnosis and indication.
FDA-approved uses
Product distinctions matter
A medication name is not enough. Wegovy, Ozempic, Rybelsus, Zepbound, and Mounjaro have different labels, indications, forms, and warnings. Ask your clinician which product is being discussed and why.
Effectiveness
Clinical studies measure outcomes in specific populations
Weight and glycemic measures
Studies may measure weight, A1c, cardiometabolic markers, discontinuation, and adverse events in defined trial populations.
No universal winner
Trial results do not replace individualized assessment of eligibility, contraindications, tolerability, access, and clinical goals.
Safety
Side effects, contraindications, and warnings need product-specific review
Ask about thyroid C-cell tumor warnings, pancreatitis symptoms, gallbladder disease, severe gastrointestinal symptoms, kidney concerns related to dehydration, diabetic retinopathy warnings where relevant, hypoglycemia risk with insulin or insulin secretagogues, hypersensitivity, and peri-procedure considerations.
Dosing and administration
Discuss the plan without self-adjusting doses
FDA labels include product-specific administration and dose-escalation instructions. Patients should not personalize dosing from internet summaries; they should follow the prescribing clinician and product label.
Access and costs
Insurance and supply can shape real-world options
Costs vary by product, diagnosis, insurance coverage, prior authorization, pharmacy access, and whether the clinic is cash-pay. Ask what total treatment costs include.
Compounded products
Compounded products are not automatically equivalent to FDA-approved products
FDA warns that unapproved versions of semaglutide and tirzepatide do not undergo FDA review for safety, effectiveness, and quality before marketing. Ask how any medication is sourced and whether an FDA-approved product could meet your medical needs.
Questions to ask
Questions to ask a GLP-1 provider
Eligibility
What diagnosis, BMI, weight-related conditions, medications, and medical history factors affect whether GLP-1 treatment is appropriate?
Medication choice
Which FDA-approved products do you prescribe, what are they approved for, and why might one fit my situation better than another?
Safety review
Which contraindications, warnings, side effects, drug interactions, and emergency symptoms should I understand before starting?
Follow-up
How often will we check symptoms, tolerability, dose changes, nutrition, muscle preservation, and long-term progress?
Costs and access
What costs are separate for visits, labs, medication, refills, prior authorization, cash-pay programs, and follow-up?
Telehealth
Which parts of care can happen virtually, and when are in-person exams, labs, or local pharmacy coordination needed?
Clinic comparison
How to choose a GLP-1 clinic
Licensed oversight
Confirm who evaluates eligibility, prescribes medication, monitors side effects, and handles follow-up questions.
Medication sourcing
Ask whether the clinic uses FDA-approved products, how prescriptions are filled, and how compounded products are discussed.
Monitoring plan
Look for structured follow-up around tolerability, nutrition, medication changes, and long-term maintenance.
Nutrition support
Compare how clinics address protein intake, strength training, muscle preservation, hydration, and sustainable habits.
Pricing clarity
Clarify appointment fees, medication costs, insurance billing, cash-pay rates, refill policies, and cancellation terms.
Access model
Ask which services are telehealth-friendly and which require in-person care, labs, or local clinical support.
Relevant providers
Relevant GLP-1 Providers
Provider links use current SpanScout GLP-1 / Weight Loss listings.
GLP-1 Providers
94
Offer Telehealth
1
Provider Types
4
Services Compared
13
| Provider | Location | Type | Telehealth | Key services | Profile action |
|---|---|---|---|---|---|
| Flow Wellness SpanScout listing | Seattle, WA | Weight Loss Clinic | Not listed | glp1semaglutideweight loss | |
| 10Rx Health SpanScout listing | Houston, TX | Weight Loss Clinic | Not listed | glp1weight losssemaglutide | |
| 1Stop Clinic SpanScout listing | Houston, TX | Weight Loss Clinic | Not listed | glp1weight losswellness | |
| 61Five Health & Wellness SpanScout listing | Nashville, TN | Weight Loss Clinic | Not listed | glp1semaglutideweight loss | |
| Advitam SpanScout listing | New York, NY | Weight Loss Clinic | Not listed | glp1weight losslongevity | |
| Age Well ATL SpanScout listing | Atlanta, GA | Weight Loss Clinic | Not listed | glp1weight losslongevity | |
| Allure Medical SpanScout listing | Charlotte, NC | Weight Loss Clinic | Not listed | glp1semaglutideweight loss | |
| Art Medica SpanScout listing | Chicago, IL | Multi-Service Clinic | Not listed | glp1semaglutideweight loss |
Next step
Ready to compare GLP-1 providers?
Use SpanScout to browse GLP-1 and medically supervised weight-loss providers, compare services, and visit provider profiles.
Find GLP-1 ProvidersFAQ
Questions before booking
What is the main difference between semaglutide and tirzepatide?
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 receptors. Product selection depends on diagnosis, eligibility, risks, access, and clinician guidance.
Is tirzepatide always better than semaglutide?
No. Studies measure specific outcomes in specific populations, but individual choice depends on indication, contraindications, tolerability, access, cost, and clinical judgment.
Are Ozempic and Wegovy the same?
They both contain semaglutide, but they have different product labels and approved uses. A clinician should explain the product being discussed.
Are compounded versions equivalent to FDA-approved products?
FDA-approved and compounded products are not the same regulatory category. FDA warns that unapproved versions do not undergo FDA review for safety, effectiveness, and quality before marketing.
Continue Exploring
Sources and disclaimer
Medical references used for this guide
Prescription Medications to Treat Overweight & Obesity
National Institute of Diabetes and Digestive and Kidney Diseases
Used for weight-management medication eligibility concepts, lifestyle context, product distinctions, and long-term treatment considerations.
FDA Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration
Used for compounded semaglutide and tirzepatide cautions, dosing-error concerns, and distinctions from FDA-approved products.
WEGOVY prescribing information
DailyMed / U.S. National Library of Medicine
Used for semaglutide weight-management indications, product-specific warnings, contraindications, and administration-form context.
ZEPBOUND prescribing information
DailyMed / U.S. National Library of Medicine
Used for tirzepatide weight-management indications, GIP/GLP-1 mechanism, limitations of use, warnings, and contraindications.
Obesity and Weight Management: Standards of Care in Diabetes - 2026
American Diabetes Association
Used for diabetes and obesity pharmacotherapy context, benefit-risk framing, long-term therapy considerations, and individualized dosing/tolerability concepts.
OZEMPIC prescribing information
DailyMed / U.S. National Library of Medicine
Used for injectable semaglutide type 2 diabetes indications, product distinction from Wegovy, warnings, and contraindications.
MOUNJARO prescribing information
DailyMed / U.S. National Library of Medicine
Used for tirzepatide type 2 diabetes indications, product distinction from Zepbound, warnings, and contraindications.
This guide is for education and provider discovery only. It does not diagnose obesity, diabetes, or any other condition, and it does not recommend a medication or dose. Talk with a qualified healthcare professional about eligibility, contraindications, product selection, monitoring, side effects, costs, and alternatives.
Trust signal
Why trust SpanScout?
SpanScout helps readers compare providers using visible listing data and provider attributes. Claimed or featured status may help identify enhanced listings, but paid placement does not replace independent comparison of services, credentials, access, and fit.
Providers cannot pay for higher placement in comparison results.